Initial psychometric evaluation of the Arm Activity Measure (ArmA): a measure of activity in the hemiparetic arm

被引:43
作者
Ashford, Stephen [1 ,2 ]
Turner-Stokes, Lynne [1 ,2 ]
Siegert, Richard [3 ]
Slade, Mike [4 ]
机构
[1] Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, Harrow HA1 3UJ, Middx, England
[2] Kings Coll London, Dept Palliat Care Policy & Rehabil, London, England
[3] AUT Univ, Dept Psychol, Auckland, New Zealand
[4] Kings Coll London, Inst Psychiat, Hlth Serv & Populat Res Dept, London, England
关键词
Psychometrics; activities; arm; UPPER-LIMB SPASTICITY; TOXIN TYPE-A; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; BOTULINUM-TOXIN; GOAL ATTAINMENT; DOUBLE-BLIND; OUTCOME MEASURES; STROKE; REHABILITATION;
D O I
10.1177/0269215512474942
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Objective: To evaluate the psychometric properties of the Arm Activity Measure (ArmA), a patient-reported measure of active and passive function in the paretic upper limb. Design: Psychometric evaluation study. Setting: Two specialist rehabilitation and spasticity management services. Method: Patients (n = 92) with upper limb paresis were recruited from two specialist neurorehabilitation centres. Mean age 44.5 (SD 16.7). Diagnostic distribution: stroke 48 (52%); other brain injury 28 (31%); or other neurological condition 16 (17%). Evaluation of convergent and divergent validity; unidimensionality, scaling, reliability (internal consistency and test-retest); responsiveness to change and feasibility of the ArmA were undertaken. Results: Expected convergent and divergent relationships were seen with the Leeds Adult Spasticity Impact Scale and the Disabilities of Arm Shoulder and Hand (DASH) (rho 0.5-0.63). Principal components analysis confirmed that active and passive function formed two separate constructs in each sub-scale. Mokken analysis corroborated the findings of the principal components analysis and demonstrated scaling using the monotone homogeneity model (Item H>0.5 for all items). Cronbach's alpha was 0.85 and 0.96, respectively, for the passive and active function subscales. Item level test-retest agreement ranged from 92-97.5% (quadratic-weighted Kappa 0.71-0.94). In the subgroup treated for spasticity with botulinum toxin (n = 58), the ArmA passive function scale identified a significant difference between responder and non-responder groups (Mann Whitney U = 0.85, p < 0.01). Respondents reported the ArmA to be relevant (77%), easy to use (90%) and timely to complete (83% under 10 minutes). Conclusion: The ArmA is a valid and reliable tool feasible for use in the evaluation of upper limb function in the context of treatment for spasticity.
引用
收藏
页码:728 / 740
页数:13
相关论文
共 41 条
[1]  
Ashford S, DISABILITY IN PRESS
[2]   Goal attainment for spasticity management using botulinum toxin [J].
Ashford, Stephen ;
Turner-Stokes, Lynne .
PHYSIOTHERAPY RESEARCH INTERNATIONAL, 2006, 11 (01) :24-34
[3]   EVALUATION OF FUNCTIONAL OUTCOME MEASURES FOR THE HEMIPARETIC UPPER LIMB: A SYSTEMATIC REVIEW [J].
Ashford, Stephen ;
Slade, Mike ;
Malaprade, Fabienne ;
Turner-Stokes, Lynne .
JOURNAL OF REHABILITATION MEDICINE, 2008, 40 (10) :787-795
[4]   The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey [J].
Bakheit, Abdel Magid ;
Zakine, Benjamin ;
Maisonobe, Pascal ;
Aymard, Claire ;
Fhedoroff, Klemens ;
Hefter, Harold ;
Jacinto, Jorge ;
Jost, Wolfgang H. ;
Molteni, Franco ;
Stam, Henk ;
Turner-Stokes, Lynne ;
Wissel, Jorg .
INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH, 2010, 33 (03) :199-204
[5]   The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles [J].
Bakheit, AMO ;
Fedorova, NV ;
Skoromets, AA ;
Timerbaeva, SL ;
Bhakta, BB ;
Coxon, L .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (11) :1558-1561
[6]   A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke [J].
Bakheit, AMO ;
Pittock, S ;
Moore, AP ;
Wurker, M ;
Otto, S ;
Erbguth, F ;
Coxon, L .
EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (06) :559-565
[7]  
Barrett P, 1981, J PERSONALITY GROUP, V1, P1
[8]   Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial [J].
Bhakta, BB ;
Cozens, JA ;
Chamberlain, MA ;
Bamford, JM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 69 (02) :217-221
[9]   Use of botulinum toxin in stroke patients with severe upper limb spasticity [J].
Bhakta, BB ;
Cozens, JA ;
Bamford, JM ;
Chamberlain, MA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (01) :30-35
[10]   Associated reactions after stroke: A randomized controlled trial of the effect of botulinum toxin type A [J].
Bhakta, Bipin B. ;
O'Connor, Rory J. ;
Cozens, J. Alastair .
JOURNAL OF REHABILITATION MEDICINE, 2008, 40 (01) :36-41